Literature DB >> 14180542

PERIPHERAL VASODILATORS IN THE TREATMENT OF MACULAR DEGENERATIVE CHANGES IN THE EYE.

H W LAWS.   

Abstract

Four peripheral vasodilators - tolazoline HCl (Priscoline), nicotinic acid, nicotinyl alcohol (Roniacol), and nylidrin HCl (Arlidin)-were studied in 203 patients over a 13-year period as treatment for macular degenerative changes in the eye.Visual acuity was improved or maintained in 87%. Excellent results were obtained in the treatment of macular edema following cataract surgery and in older patients with diabetic retinopathy. In 126 out of 145 patients with senile macular degeneration, improvement or stabilization was obtained.For all the types of macular degeneration, nylidrin HCl was the most effective of the drugs studied and had the fewest side effects.A recent report based upon animal experiments advises against the use of peripheral vasodilators in degenerative arterial diseases of the eye; however, the assumption made therein that blood volume is a measure of blood flow cannot be accepted. Peripheral vasodilator therapy, which long-term clinical study has shown to be valuable in the treatment of macular degeneration, should not therefore be denied to these patients.

Entities:  

Keywords:  BLOOD FLOW VELOCITY; BLOOD VOLUME; CATARACT EXTRACTION; CHOROID; DIABETIC RETINOPATHY; DRUG THERAPY; EDEMA; GERIATRICS; HISTORY; MACULA LUTEA; NICOTINIC ACID; OPHTHALMOLOGY; RETINA; TOLAZOLINE; TOXICOLOGIC REPORT; VASCULAR DISEASES; VASODILATOR AGENTS

Mesh:

Substances:

Year:  1964        PMID: 14180542      PMCID: PMC1927463     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  9 in total

1.  Effect of peripheral vasodilator and vasoconstrictor drugs on the intraocular (choroidal) blood volume.

Authors:  J W BETTMAN; V FELLOWS
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1962 Jul-Aug

2.  The cerebral peripheral circulatory action of nylidrin hydrochloride.

Authors:  T WINSOR; C HYMAN; F M KNAPP
Journal:  Am J Med Sci       Date:  1960-05       Impact factor: 2.378

3.  Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy.

Authors:  S VANNAS; H ORMA
Journal:  AMA Arch Ophthalmol       Date:  1957-12

4.  Treatment of retinal artery occlusions.

Authors:  L M WEEREKOON
Journal:  Am J Ophthalmol       Date:  1957-06       Impact factor: 5.258

5.  Spasm and organic arterial lesions in the retina.

Authors:  H P WAGENER
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1958 May-Jun

6.  The effects of a new drug, nylidrin, upon the electroretinogram.

Authors:  D BASAR; J H JACOBSON
Journal:  AMA Arch Ophthalmol       Date:  1956-12

7.  Studies with dilatol, a vasodilator substance.

Authors:  A G RIDDELL; M STEEL; J M McCOY
Journal:  Angiology       Date:  1954-08       Impact factor: 3.619

8.  On the character and management of circulatory disturbances of the central retina.

Authors:  J V V NICHOLLS
Journal:  Am J Ophthalmol       Date:  1952-12       Impact factor: 5.258

9.  The effect of nylidrin hydrochloride (arlidin) on the cerebral circulation.

Authors:  S EISENBERG
Journal:  Am J Med Sci       Date:  1960-07       Impact factor: 2.378

  9 in total
  1 in total

1.  Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Chelsea E Myers; Barbara E K Klein
Journal:  Ophthalmology       Date:  2014-04-29       Impact factor: 12.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.